エレバンスヘルスの適時開示・決算

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

July 17, 2024

Date of Report (Date of earliest event reported)

___________________________________

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________


Indiana (State or other jurisdiction of incorporation or organization)			001-16751 (Commission File Number)			35-2145715 (I.R.S. Employer Identification Number)

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices and zip code)

(833) 401-1577

(Registrant's telephone number, including area code)

________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $0.01	ELV	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 - Results of Operations and Financial Condition.

On July 17, 2024, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

None of the information furnished in Item 2.02 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.			Exhibit
99.1			Press Release, dated July 17, 2024, reporting Elevance Health, Inc. financial results for the quarter ended June 30, 2024.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 17th day of July, 2024.


ELEVANCE HEALTH, INC.

By:			/s/ Kathleen S. Kiefer
Name:			Kathleen S. Kiefer
Title:			Chief Governance Officer and Corporate Secretary

EX-99.1 2 a2q2024elvearningsrelease.htm EX-99.1 Document

E A R N I N G S R E L E A S E

ELEVANCE HEALTH REPORTS SECOND QUARTER 2024 RESULTS

•2Q 2024 operating revenue of $43.2 billion

•2Q 2024 adjusted operating gain1 of $2.8 billion

•2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12%

•3Q 2024 dividend of $1.63 per share declared to shareholders

Indianapolis, IN - July 17, 2024 - Elevance Health, Inc. (NYSE: ELV) reported second quarter 2024 results.

“Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our long-term targets.”

Gail K. Boudreaux

President and Chief Executive Officer

1.Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.

2.Earnings per diluted share ("EPS").



Elevance Health
Consolidated Enterprise Highlights
(Unaudited)

(In billions)	Three Months Ended
	June 30, 2024		June 30, 2023		March 31, 2024






Operating Revenue1	$43.2		$43.4		$42.3





Operating Gain1,2	$2.8		$2.6		$3.0




Operating Margin1	6.4	%	6.1	%	7.1	%

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three months ended June 30, 2024, and June 30, 2023, include items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

Operating revenue was $43.2 billion in the second quarter of 2024, a decrease of $0.2 billion compared to the prior year quarter. This decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields to reflect medical cost trend, and growth in CarelonRx product revenue related to members served.

The benefit expense ratio was 86.3 percent, an improvement of 10 basis points, driven primarily by premium rate adjustments to cover medical cost trend in our Health Benefits business and disciplined commercial underwriting. Days in Claims Payable was 45.3 days as of June 30, 2024, a decrease of 3.7 days from March 31, 2024, including a 1.7 day decline related to industry-wide delays earlier this year in claims receipts, and a decrease of 1.2 days compared to June 30, 2023, principally on improved operational efficiency.

The operating expense ratio was 11.7 percent, an increase of 60 basis points driven by targeted investment and integration costs. Excluding adjustment items, the operating expense ratio was 11.5 percent, an increase of 50 basis points.

Elevance Health expects GAAP net income per diluted share to be at least $34.05 in 2024, and adjusted diluted net income per share to be at least $37.20.

Cash Flow & Balance Sheet

Operating cash flow was $2.4 billion year-to-date, a decrease of $6.0 billion year-over-year, including $4.3 billion of timing-related items and $1.3 billion of net cash outflows associated with medical claims payable, principally due to lower Medicaid membership. As of June 30, 2024, cash and investments at the parent company totaled approximately $2.4 billion.

During the second quarter of 2024, the Company repurchased 0.9 million shares of its common stock for $462 million, at a weighted average price of $524.55, and paid a quarterly dividend of $1.63 per share, representing a distribution of cash totaling $378 million. As of June 30, 2024, the Company had approximately $3.2 billion of Board approved share repurchase authorization remaining.

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Health Products & Services businesses.



Health Benefits
Reportable Segment Highlights
(Unaudited)

(In billions)	Three Months Ended
	June 30, 2024		June 30, 2023		March 31, 2024

Operating Revenue1	$37.2		$38.0		$37.3
Operating Gain1,2	$2.1		$2.1		$2.3

Operating Margin1	5.8	%	5.6	%	6.1	%

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three months ended June 30, 2023, has been restated for the realignment of Carelon Global Solutions. See footnote 2 to the Reportable Segment Highlight Details table on page 11.

Health Benefits segment operating revenue was $37.2 billion in the second quarter of 2024, a decrease of 2 percent compared to the prior year quarter, as Medicaid membership attrition was only partially offset by premium rate increases to reflect medical cost trends, and growth in Individual Affordable Care Act health plan membership.

Operating gain totaled $2.1 billion, which was unchanged compared to the prior year.

Medical membership totaled approximately 45.8 million as of June 30, 2024, a decrease of 2.2 million, or 5 percent compared to the prior year quarter, driven by attrition in our Medicaid business associated with eligibility redeterminations and footprint adjustments, primarily in the first quarter. These losses were partially offset by growth in our Affordable Care Act health plans and commercial Employer Group fee-based membership.

Carelon is comprised of CarelonRx and Carelon Services.



Carelon
Reportable Segment Highlights
(Unaudited)

(In billions)	Three Months Ended
	June 30, 2024		June 30, 2023		March 31, 2024



Operating Revenue1,2	$13.3		$12.1		$12.1






Operating Gain1,2	$0.7		$0.7		$0.8





Operating Margin1	5.3	%	5.4	%	6.7	%

1.See “Basis of Presentation” on page 5 herein.

2.For the Operating Revenue and Operating Gain of CarelonRx and Carelon Services for the three months ended June 30, 2024, and June 30, 2023, see the Reportable Segment Highlight Details table on page 11, which has been restated for the realignment of Carelon Global Solutions. See footnote 2 on page 11 for details.

Operating revenue for Carelon was $13.3 billion in the second quarter of 2024, an increase of $1.2 billion, or 10 percent compared to the prior year quarter. This increase was driven by the launch and growth of risk-based medical benefit and behavioral health management services in Carelon Services, as well as growth in CarelonRx product revenue related to external members served and the acquisition of Paragon Healthcare in the first quarter.

Operating gain for Carelon totaled $0.7 billion, an increase of $52 million, or 8 percent, primarily driven by improved performance on risk-based arrangements in Carelon Services.

Quarterly Dividend

On July 16, 2024, the Audit Committee of the Company's Board of Directors declared a third quarter 2024 dividend to shareholders of $1.63 per share. The third quarter dividend is payable on September 25, 2024, to shareholders of record at the close of business on September 10, 2024.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve over 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s second quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:


888-947-9963 (Domestic)			800-391-9851 (Domestic Replay)
312-470-0178 (International)			203-369-3268 (International Replay)

The access code for today's conference call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT today, until the end of the day on August 16, 2024. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

Basis of Presentation

1.Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.

2.Operating margin is defined as operating gain divided by operating revenue.


Elevance Health Contacts:

Investor Relations			Media
Stephen Tanal			Leslie Porras
Investor.Relations@elevancehealth.com			Leslie.Porras@elevancehealth.com

Elevance Health

Earnings Release Financial Schedules and Supplementary Information

Quarter & Year-to-Date Ended June 30, 2024

•Membership and Other Metrics

•Quarterly & Year-to-Date Consolidated Statements of Income

•Condensed Consolidated Balance Sheet

•Condensed Consolidated Statement of Cash Flows

•Supplemental Financial Information - Reportable Segments

•Supplemental Financial Information - Reconciliation of Medical Claims Payable

•Reconciliation of Non-GAAP Financial Measures


Elevance Health
Membership and Other Metrics
(Unaudited)

				Change from
Medical Membership (in thousands)	June 30, 2024	June 30, 2023	March 31, 2024	June 30, 2023		March 31, 2024
Individual	1,281	949	1,246	35.0	%	2.8	%
Employer Group Risk-Based	3,648	3,765	3,648	(3.1)	%	—	%
Commercial Risk-Based	4,929	4,714	4,894	4.6	%	0.7	%
BlueCard®1	6,692	6,720	6,635	(0.4)	%	0.9	%
Employer Group Fee-Based	20,542	20,160	20,622	1.9	%	(0.4)	%
Commercial Fee-Based	27,234	26,880	27,257	1.3	%	(0.1)	%
Medicare Advantage	2,031	2,059	2,017	(1.4)	%	0.7	%
Medicare Supplement	894	926	896	(3.5)	%	(0.2)	%
Total Medicare	2,925	2,985	2,913	(2.0)	%	0.4	%
Medicaid	9,028	11,759	9,327	(23.2)	%	(3.2)	%
Federal Employees Health Benefits	1,660	1,634	1,658	1.6	%	0.1	%
Total Medical Membership	45,776	47,972	46,049	(4.6)	%	(0.6)	%
Other Membership (in thousands)


Dental Members	7,008	6,728	6,970	4.2	%	0.5	%
Dental Administration Members	1,851	1,694	1,841	9.3	%	0.5	%
Vision Members	10,275	9,850	10,251	4.3	%	0.2	%
Medicare Part D Standalone Members	260	263	262	(1.1)	%	(0.8)	%
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts	78.2	77.4	77.0	1.0	%	1.6	%
Carelon Services Consumers Served	102.3	103.6	102.9	(1.3)	%	(0.6)	%

1.BlueCard® membership for the three months ended June 30, 2023, and March 31, 2024, are restated to align to the Blue Cross Blue Shield Association reporting methodology. For the three months ended June 30, 2023, and the three months ended March 31, 2024, BlueCard® membership has been restated lower by 17 and 190, respectively.


Elevance Health
Consolidated Statements of Income
(Unaudited)
(In millions, except per share data)	Three Months Ended June 30								Six Months Ended June 30
	2024			2023			Change		2024			2023			Change

Revenues
Premiums	$	35,416		$	36,589		(3.2)%		$	71,112		$	72,457		(1.9)%
Product revenue	5,530			4,859			13.8%		10,029			8,881			12.9%
Service fees	2,277			1,929			18.0%		4,355			3,937			10.6%
Total operating revenue	43,223			43,377			(0.4)%		85,496			85,275			0.3%
Net investment income	508			416			22.1%		973			803			21.2%
Net losses on financial instruments	(85)			(121)			NM		(246)			(234)			NM
Gain on sale of business	240			—			NM		240			—			NM
Total revenues	43,886			43,672			0.5%		86,463			85,844			0.7%
Expenses
Benefit expense	30,572			31,604			(3.3)%		61,118			62,390			(2.0)%
Cost of products sold	4,820			4,327			11.4%		8,645			7,808			10.7%



Operating expense	5,066			4,818			5.1%		9,952			9,618			3.5%
Interest expense	280			261			7.3%		545			512			6.4%
Amortization of other intangible assets	162			221			(26.7)%		278			456			(39.0)%

Total expenses	40,900			41,231			(0.8)%		80,538			80,784			(0.3)%

Income before income tax expense	2,986			2,441			22.3%		5,925			5,060			17.1%

Income tax expense	685			585			17.1%		1,375			1,200			14.6%
Net income	2,301			1,856			24.0%		4,550			3,860			17.9%

Net income attributable to noncontrolling interests	(1)			(3)			NM		(4)			(18)			NM
Shareholders' net income	$	2,300		$	1,853		24.1%		$	4,546		$	3,842		18.3%
Shareholders' earnings per diluted share	$	9.85		$	7.79		26.4%		$	19.44		$	16.10		20.7%
Diluted shares	233.4			237.8			(1.9)%		233.8			238.7			(2.1)%

Benefit expense as a percentage of premiums	86.3		%	86.4		%	(10)	bp	85.9		%	86.1		%	(20)	bp
Operating expense as a percentage of total operating revenue	11.7		%	11.1		%	60	bp	11.6		%	11.3		%	30	bp
Income before income tax expense as a percentage of total revenue	6.8		%	5.6		%	120	bp	6.9		%	5.9		%	100	bp

"NM" = calculation not meaningful


Elevance Health
Condensed Consolidated Balance Sheet
(In millions)	June 30, 2024		December 31, 2023
Assets	(Unaudited)
Current assets:
Cash and cash equivalents	$	6,497	$	6,526
Fixed maturity and equity securities	29,494		29,843
Premium and other receivables	19,218		17,865
Other current assets	6,464		5,795
Assets held for sale	601		$	—
Total current assets	62,274		60,029

Long-term investments	7,659		6,983
Property and equipment, net	4,450		4,359
Goodwill and other intangible assets	36,409		35,590
Other noncurrent assets	2,196		1,967
Total assets	$	112,988	$	108,928

Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable	$	15,204	$	16,111
Short-term borrowings	225		225
Current portion of long-term debt	2,900		1,649
Other current liabilities	23,319		23,806
Liabilities held for sale	165		$	—
Total current liabilities	41,813		41,791

Long-term debt, less current portion	24,561		23,246
Other noncurrent liabilities	4,317		4,486
Total liabilities	70,691		69,523






Total shareholders’ equity	42,191		39,306
Noncontrolling interests	106		99
Total equity	42,297		39,405
Total liabilities and equity	$	112,988	$	108,928


Elevance Health
Condensed Consolidated Statement of Cash Flows
(Unaudited)

(In millions)	Six Months Ended June 30
	2024		2023

Operating activities
Net income	$	4,550	$3,860



Depreciation and amortization	666		895
Share-based compensation	154		139
Changes in operating assets and liabilities	(2,943)		3,611
Other non-cash items	(2)		(86)
Net cash provided by operating activities	2,425		8,419

Investing activities
Purchases of investments, net of sales and maturities	(1,415)		(1,653)



Purchases of subsidiaries, net of cash acquired	(725)		(1,651)

Purchases of property and equipment	(602)		(651)
Other, net	(386)		99
Net cash used in investing activities	(3,128)		(3,856)

Financing activities
Net change in short-term and long-term borrowings	2,580		666





Repurchase and retirement of common stock	(1,029)		(1,268)
Cash dividends	(757)		(701)


Other, net	(94)		(658)
Net cash provided by (used in) financing activities	700		(1,961)

Effect of foreign exchange rates on cash and cash equivalents	(5)		2

Change in cash and cash equivalents	(8)		2,604
Cash and cash equivalents at beginning of period	6,526		7,387
Less cash and equivalents included in assets held for sale at end of period	(21)		—

Cash and cash equivalents at end of period	$6,497		$9,991

REPORTABLE SEGMENTS

Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Health Products & Services businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments).



Elevance Health
Reportable Segment Highlight Details
(Unaudited)

(In millions)	Three Months Ended June 30						Six Months Ended June 30
	2024		2023		Change		2024		2023		Change

Operating Revenue
Health Benefits	$37,159		$38,000		(2.2)	%	$74,417		$75,280		(1.1)	%
CarelonRx	8,774		8,466		3.6	%	16,841		16,490		2.1	%
Carelon Services2	4,545		3,604		26.1	%	8,554		7,064		21.1	%
Corporate & Other2	122		112		8.9	%	249		203		22.7	%
Eliminations2	(7,377)		(6,805)		8.4	%	(14,565)		(13,762)		5.8	%
Total Operating Revenue1	$43,223		$43,377		(0.4)	%	$85,496		$85,275		0.3	%

Operating Gain (Loss)
Health Benefits2	$2,145		$2,138		0.3	%	$4,432		$4,287		3.4	%
CarelonRx	497		496		0.2	%	1,020		1,008		1.2	%
Carelon Services2	208		157		32.5	%	498		386		29.0	%
Corporate & Other2,3	(85)		(163)		NM4		(169)		(222)		NM4
Total Operating Gain1	$2,765		$2,628		5.2	%	$5,781		$5,459		5.9	%

Operating Margin
Health Benefits	5.8	%	5.6	%	20 bp		6.0	%	5.7	%	30 bp
CarelonRx	5.7	%	5.9	%	(20) bp		6.1	%	6.1	%	— bp
Carelon Services	4.6	%	4.4	%	20 bp		5.8	%	5.5	%	30 bp
Total Operating Margin1	6.4	%	6.1	%	30 bp		6.8	%	6.4	%	40 bp

1.See “Basis of Presentation” on page 5 herein.

2.Operating Revenue and Operating Gain for the three and six months ended June 30, 2023, are restated for the realignment of Carelon Global Solutions. For the three and six months ended June 30, 2023, $163 and $311 of Operating Revenue was realigned to Carelon Services, $175 and $335 of Operating Revenue was realigned away from the Corporate & Other segment, and $12 and $24 of Operating Revenue was realigned to Eliminations. For the three and six months ended June 30, 2023, $21 and $41 of Operating Gain was realigned to Carelon Services, $10 and $20 of Operating Gain was realigned away from the Health Benefits segment, and $11 and $21 of Operating Gain was realigned away from Corporate & Other.

3.Operating Gain for the three months ended June 30, 2024, and June 30, 2023, included items adjusted out of adjusted shareholders' net income. See "GAAP Reconciliation" on page 13 and 14 herein.

4."NM" = calculation not meaningful.


Elevance Health
Reconciliation of Medical Claims Payable

	Six Months Ended June 30						Years Ended December 31
	2024			2023			2023			2022			2021
(In millions)	(Unaudited)			(Unaudited)

Gross medical claims payable, beginning of period	$	15,865		$	15,348		$	15,348		$	13,282		$	11,135
Ceded medical claims payable, beginning of period	(7)			(6)			(6)			(21)			(46)
Net medical claims payable, beginning of period	15,858			15,342			15,342			13,261			11,089

Business combinations and purchase adjustments	—			—			—			133			420

Net incurred medical claims:
Current year	60,551			61,290			121,798			113,414			100,440
Prior years redundancies1	(1,473)			(1,112)			(1,571)			(869)			(1,703)
Total net incurred medical claims	59,078			60,178			120,227			112,545			98,737

Net payments attributable to:
Current year medical claims	48,297			48,217			107,146			98,997			88,156
Prior years medical claims	11,584			11,409			12,565			11,600			8,829
Total net payments	59,881			59,626			119,711			110,597			96,985

Net medical claims payable, end of period	15,055			15,894			15,858			15,342			13,261
Ceded medical claims payable, end of period	12			8			7			6			21
Gross medical claims payable, end of period2	$	15,067		$	15,902		$	15,865		$	15,348		$	13,282

Current year medical claims paid as a percentage of current year net incurred medical claims	79.8		%	78.7		%	88.0		%	87.3		%	87.8		%

Prior year redundancies in the current year as a percentage of prior year net medical claims payable less prior year redundancies in the current year	10.2		%	7.8		%	11.4		%	7.0		%	18.1		%

Prior year redundancies in the current year as a percentage of prior year net incurred medical claims	1.2		%	1.0		%	1.4		%	0.9		%	2.0		%

1.Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

2.Excludes insurance lines other than short duration.

Elevance Health

GAAP Reconciliation

(Unaudited)

This document references non-GAAP measures, including “Adjusted Shareholders’ Net Income,” “Adjusted Shareholders’ Net Income Per Share,” “Adjusted EPS,” “Adjusted Operating Gain,” “Adjusted Operating Expense” and “Adjusted Operating Expense Ratio,” which are non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain/Loss,” “Operating Margin” and “Adjusted EPS”. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain to income before income tax expense, is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein.


	Three Months Ended June 30						Six Months Ended June 30
(In millions, except per share data)	2024		2023		Change		2024		2023		Change
Shareholders' net income	$	2,300	$	1,853	24.1	%	$	4,546	$	3,842	18.3	%
Add / (Subtract):
Amortization of other intangible assets	162		221				278		456
Net losses on financial instruments	85		121				246		234
Transaction and integration related costs1	64		55				116		81



Litigation and settlement expenses1	9		2				11		3
Business optimization charges1	4		—				—		—

Gain on sale of business	(240)		—				(240)		—
Tax impact of non-GAAP adjustments	(22)		(103)				(103)		(200)
Net adjustment items	62		296				308		574
Adjusted shareholders' net income	$	2,362	$	2,149	9.9	%	$	4,854	$	4,416	9.9	%

Shareholders' earnings per diluted share	$	9.85	$	7.79	26.4	%	$	19.44	$	16.10	20.7	%
Add / (Subtract):
Amortization of other intangible assets	0.69		0.93				1.19		1.91
Net losses on financial instruments	0.36		0.51				1.05		0.98
Transaction and integration related costs1	0.27		0.23				0.50		0.34



Litigation and settlement expenses1	0.04		0.01				0.05		0.01
Business optimization charges1	0.02		—				—		—

Gain on sale of business	(1.03)		—				(1.03)		—

Tax impact of non-GAAP adjustments	(0.09)		(0.43)				(0.44)		(0.84)

Net adjustment items	0.27		1.25				1.32		2.40
Adjusted shareholders' earnings per diluted share	$	10.12	$	9.04	11.9	%	$	20.76	$	18.50	12.2	%

	Three Months Ended June 30						Six Months Ended June 30
(In millions)	2024		2023		Change		2024		2023		Change

Income before income tax expense	$	2,986	$	2,441	22.3	%	$	5,925	$	5,060	17.1	%
Net investment income	(508)		(416)				(973)		(803)
Gain on sale of business	(240)		—				(240)		—
Net losses on financial instruments	85		121				246		234
Interest expense	280		261				545		512
Amortization of other intangible assets	162		221				278		456


Reportable segments operating gain	$	2,765	$	2,628	5.2	%	$	5,781	$	5,459	5.9	%

1.Adjustment item resides in the Corporate & Other reportable segment.

Elevance Health

GAAP Reconciliation

(Unaudited)


	Three Months Ended June 30								Six Months Ended June 30
(In millions)	2024			2023			Change		2024			2023			Change

Reportable segments operating gain	$	2,765		$	2,628		5.2	%	$	5,781		$	5,459		5.9	%
Add / (Subtract):
Transaction and integration related costs1	64			55					116			81
Litigation and settlement expenses1	9			2					11			3
Business optimization charges1	4			—					—			—

Net adjustment items	77			57					127			84
Reportable segments adjusted operating gain	$	2,842		$	2,685		5.8	%	$	5,908		$	5,543		6.6	%

	Three Months Ended June 30								Six Months Ended June 30
(In millions)	2024			2023			Change		2024			2023			Change
Operating expense	$	5,066		$	4,818		5.1	%	$	9,952		$	9,618		3.5	%
Add / (Subtract):




Transaction and integration related costs1	(64)			(55)					(116)			(81)
Litigation and settlement expenses1	(9)			(2)					(11)			(3)
Business optimization charges1	(4)			—					—			—





Net adjustment items	(77)			(57)					(127)			(84)
Adjusted operating expense	$	4,989		$	4,761		4.8	%	$	9,825		$	9,534		3.1	%

Operating revenue	$	43,223		$	43,377		(0.4)	%	$	85,496		$	85,275		0.3	%

Operating expense ratio	11.7		%	11.1		%	60 bp		11.6		%	11.3		%	30 bp
Adjusted operating expense ratio	11.5		%	11.0		%	50 bp		11.5		%	11.2		%	30 bp

















	Full Year 2024 Outlook
Shareholders' earnings per diluted share	At least $34.05
Add / (Subtract):
Amortization of other intangibles	$2.18


Net losses on financial instruments	$1.61
Transaction and integration related costs1	$1.21
Litigation and settlement expenses1	$0.07


Gain on sale of business	($1.03)
Tax impact of non-GAAP adjustments	Approximately ($0.89)
Net adjustment items	$3.15
Adjusted shareholders' earnings per diluted share	At least $37.20

1.Adjustment item resides in the Corporate & Other reportable segment.

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.